Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Open accessThe DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockade (ICB) has a limited effect on colorectal cancer, underlining the requirement of co‐targeting the complementary mechanisms. Here, we identified prostaglandin E2 (PGE 2 ) receptor 4 (EP4) as the master regulator of immunosuppressive myeloid cells (IMCs), which are the major driver of resistance to ICB therapy. PGE 2 ‐bound EP4 promotes the differentiation of immunosuppressive M2 macrophages and myeloid‐derived suppressor cells (MDSCs) and reduces the expansion of immunostimulated M1 macrophages. To explore the immunotherapeutic role of EP4 signaling, we developed a novel and selective EP4 antagonist TP‐16. TP‐16 effectively blocked the function of IMCs and enhanced cytotoxic T‐cell‐mediated tumor elimination in vivo . Cell co‐culture experiments revealed that TP‐16 promoted T‐cell proliferation, which was impaired by tumor‐derived CD11b + myeloid cells. Notably, TP‐16 and anti‐PD‐1 combination therapy significantly impeded tumor progression and prolonged mice survival. We further demonstrated that TP‐16 increased responsiveness to anti‐PD‐1 therapy in an IMC‐related spontaneous colorectal cancer mouse model. In summary, this study demonstrates that inhibition of EP4‐expressing IMCs may offer a potential strategy for enhancing the efficacy of immunotherapy for colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional preclinical studies showed that repolarizing TAMs enhanced T-cell-mediated anti-tumor immune response and improved the efficacy of ICIs in CRC tumors [234,235].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [234]
In the citing paper
“which enhanced T-cell-mediated anti-tumor immunity and improved the efficacy of anti-PD-1 [58].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [58]
In the citing paper
“TP-16 (EP4 antagonist) treatment polarized TAM from immunosuppressive M2 type to pro-inflammatory M1 type”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [58]
In the citing paper
“Preclinical studies show that prostaglandin E2 (PGE2) receptor 4 (EP4), as the primary regulator of IMC, can mediate drug resistance by promoting the differentiation and proliferation of M2 TAM and MDSC [58].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“In 2018, more than 1.8 million new cases and 881,000 deaths were reported worldwide (Bray et al, 2018).”
BackgroundInfluentialAutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486 · cited 1×
“To investigate the detailed interaction between EP4 and TP-16, in silico molecular docking was performed using AutoDock (Morris et al, 2009).”
MethodSiegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · cited 1×
“Colorectal cancer has a high incidence and mortality rate (Siegel et al, 2019).”
BackgroundColorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880 · cited 1×
“The prognosis for patients with distantstage disease is dismal, with a 5-year relative survival rate of only 14% (Siegel et al, 2020).”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“For instance, anti-CTLA4 antibody was approved for metastatic melanoma, and anti-PD-(L)1 antibodies were approved for a wide range of cancer types, such as melanoma, lung cancer, and renal carcinoma (Topalian et al, 2015; Patel & Minn, 2018).”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“IMCs mainly comprise tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) (Gabrilovich et al, 2012).”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · cited 1×
“Diverse regulatory mechanisms are exploited by cancer cells to establish a strong immunosuppressive tumor microenvironment that supports tumor growth, fuels tumor immune escape, and weakens immunotherapeutic efficacy (Zou, 2005; Fleming et al, 2018).”
BackgroundThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008 · cited 1×
“A high frequency of MDSCs is generally associated with poor disease progression and therapy resistance in colorectal cancer (Solito et al, 2011; Marvel & Gabrilovich, 2015; Kumar et al, 2016).”
BackgroundImmunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954 · cited 1×
“Immune checkpoint blockade (ICB) has emerged as the standard therapy for many cancers due to its unprecedented and durable responses in patients with refractory cancers (Hoos, 2016; Ganesh et al, 2019).”
BackgroundBöttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · cited 1×
“For instance, tumorderived PGE2 drives cancer progression by impairing natural killer cells and the conventional dendritic cell resulting in cancer immune evasion (Zelenay et al, 2015; Bottcher et al, 2018).”
BackgroundRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474 · cited 1×
“EP2 and EP4, two GPCRs, are considered executors of immune modulation activity of PGE2 (Kalinski, 2012).”
BackgroundThun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433 · cited 1×
“Several studies have shown that COX inhibitors, which include nonsteroidal anti-inflammatory drugs (NSAIDs), reduce the risk of cancer incidence and death due to advanced malignant diseases such as colorectal cancer (Thun et al, 2002; Gurpinar et al, 2014).”
BackgroundTumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262 · cited 1×
“TAMs accumulation is associated with poor prognosis and is a potential diagnostic biomarker for treatment stratification (Steidl et al, 2010; Lu-Emerson et al, 2013).”
BackgroundSugimoto, Y., & Narumiya, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r600038200 · Cited by 1,196 · cited 1×
“Among these receptors, EP4 is highly expressed in IMCs and plays an important role in the differentiation of TAMs and MDSCs in the tumor microenvironment (Sinha et al, 2007; Sugimoto & Narumiya, 2007).”
BackgroundPI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173 · cited 2×
“The STAT3 and AKT pathways play a critical role in regulating myeloid lineage cells (Gabrilovich et al, 2012; Kaneda et al, 2016).”
BackgroundCyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128 · cited 1×
“For instance, tumorderived PGE2 drives cancer progression by impairing natural killer cells and the conventional dendritic cell resulting in cancer immune evasion (Zelenay et al, 2015; Bottcher et al, 2018).”
BackgroundMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050 · cited 1×
“A high frequency of MDSCs is generally associated with poor disease progression and therapy resistance in colorectal cancer (Solito et al, 2011; Marvel & Gabrilovich, 2015; Kumar et al, 2016).”
BackgroundPitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041 · cited 1×
“However, the activity is lost in the microsatellite-stable (MSS) population, representing the majority of colorectal cancer patients (Pitt et al, 2016; Overman et al, 2018).”
BackgroundWang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860 · cited 4×
“For macrophages analysis (De Henau et al, 2016; Tan et al, 2018), mouse BM cells were polarized into M1 macrophages or M2 macrophages using IFN-c or IL-4, respectively.”
BackgroundMethodInfluentialHelft, J., Böttcher, J., Chakravarty, P., Zelenay, S., Huotari, J., Schraml, B. U., Goubau, D., & Reis e Sousa, C. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.018 · Cited by 812
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 1×
“IMCs, including TAMs and MDSCs, are the major drivers of an immunosuppressive tumor microenvironment and can contribute to resistance to ICB therapy (Highfill et al, 2014; De Henau et al, 2016), highlighting the potential for further improvements by combining specific IMC-targeted therapeutics.”
BackgroundSelf-citationPRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
Kroeze, W. K., Sassano, M. F., Huang, X.-P., Lansu, K., McCorvy, J. D., Giguère, P. M., Sciaky, N., & Roth, B. L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3014 · Cited by 755 · cited 1×
“EP4 recruits barrestin, and the Tango is a validated assay for evaluating ligandinduced GPCR/b-arrestin 2 interaction (Kroeze et al, 2015).”
BackgroundProstaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4174 · Cited by 755 · cited 1×
“Among these receptors, EP4 is highly expressed in IMCs and plays an important role in the differentiation of TAMs and MDSCs in the tumor microenvironment (Sinha et al, 2007; Sugimoto & Narumiya, 2007).”
BackgroundSostres, C., Gargallo, C. J., Arroyo, M. T., & Lanas, A. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.11.005 · Cited by 685 · cited 1×
“…clinical, and epidemiological data have indicated that prolonged COX-PGE2 inhibition with NSAIDs at high dosages is associated with an increased risk of gastrointestinal and cardiovascular events compared with non-NSAIDs (Mukherjee et al, 2001; Wang & Dubois, 2006; Sostres et al, 2010).”
BackgroundNeufert, C., Becker, C., & Neurath, M. F. (2007) · Nature Protocols · doi:10.1038/nprot.2007.279 · Cited by 675 · cited 1×
“…effective in AOM/DSS-induced colorectal cancer model The azoxymethane/dextran sodium sulfate (AOM/DSS) model, a chronic inflammation-induced colon cancer model with increased PGE2 generation and IMCs infiltration, reflects the pathological process of human colorectal cancer (Neufert et al, 2007).”
BackgroundKRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · cited 2×
“…Molecular Medicine 13: e12798 | 2021 1 of 20 2 of 20 EMBO Molecular Medicine 13: e12798 | 2021 ª 2020 The Authors Increasing evidence has indicated that immunosuppressive myeloid cells (IMCs) are a prominent driver of immunotherapy resistance in colorectal cancer (Le et al, 2017; Liao et al, 2019).”
BackgroundDevelopment of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589 · cited 1×
“Emerging evidence has indicated that COX2 overexpression in cancer cells dictates the immune landscape of tumors (Wellenstein & de Visser, 2018).”
BackgroundHossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 588
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573 · cited 1×
“For instance, anti-CTLA4 antibody was approved for metastatic melanoma, and anti-PD-(L)1 antibodies were approved for a wide range of cancer types, such as melanoma, lung cancer, and renal carcinoma (Topalian et al, 2015; Patel & Minn, 2018).”
BackgroundPrima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612920114 · Cited by 494 · cited 1×
“Tumor-derived PGE2 has been reported to increase the expression of immunosuppressive molecule PD-L1 in IMCs (Prima et al, 2017); however, the involvement of EP subtypes is not defined.”
BackgroundTargeting cyclooxygenase-2 in human neoplasia
Dannenberg, A. J., & Subbaramaiah, K. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00310-6 · Cited by 446 · cited 2×
“COX2, which catalyzes the biosynthesis of prostanoids, is overexpressed in most colorectal cancer tissues (Dannenberg & Subbaramaiah, 2003).”
BackgroundTargeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443 · cited 1×
“Diverse regulatory mechanisms are exploited by cancer cells to establish a strong immunosuppressive tumor microenvironment that supports tumor growth, fuels tumor immune escape, and weakens immunotherapeutic efficacy (Zou, 2005; Fleming et al, 2018).”
BackgroundSong, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T. J., Li, J., Dorosheva, O., Liu, T., Liu, R., & Huang, L. (2018) · Nature Communications · doi:10.1038/s41467-018-04605-x · Cited by 375 · cited 1×
“An orthotopic colon cancer model was established as described previously (Hite et al, 2018; Song et al, 2018).”
MethodSolito, S., Falisi, E., Diaz-Montero, C. M., Doni, A., Pinton, L., Rosato, A., Francescato, S., Basso, G., Zanovello, P., Onicescu, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325753 · Cited by 337 · cited 1×
“A high frequency of MDSCs is generally associated with poor disease progression and therapy resistance in colorectal cancer (Solito et al, 2011; Marvel & Gabrilovich, 2015; Kumar et al, 2016).”
BackgroundProstaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor
Takayama, K., Garcı́a-Cardeña, G., Sukhova, G. K., Comander, J., Gimbrone, M. A., & Libby, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204810200 · Cited by 337 · cited 1×
“For instance, several previous studies have shown that EP4 is the prominent prostaglandin receptor in human and mouse macrophages (Nataraj et al, 2001; Takayama et al, 2002).”
BackgroundReceptors for prostaglandin E2 that regulate cellular immune responses in the mouse
Nataraj, C., Thomas, D. W., Tilley, S. L., Nguyen, M., Mannon, R. B., Koller, B. H., & Coffman, T. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13640 · Cited by 287 · cited 1×
“For instance, several previous studies have shown that EP4 is the prominent prostaglandin receptor in human and mouse macrophages (Nataraj et al, 2001; Takayama et al, 2002).”
BackgroundCREB pathway links PGE2 signaling with macrophage polarization
Luan, B., Yoon, Y.-S., Le Lay, J., Kaestner, K. H., Hedrick, S., & Montminy, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519644112 · Cited by 280 · cited 1×
“Prostaglandin E2 (PGE2), a bioactive lipid with pro-tumor activity, acts through several mechanisms in colorectal cancer (Obermajer & Kalinski, 2012; Luan et al, 2015; Martinez-Colon & Moore, 2018).”
BackgroundReceptors for prostaglandin E2 that regulate cellular immune responses in the mouse
Nataraj, C., Thomas, D. W., Tilley, S. L., Nguyen, M., Mannon, R., Koller, B. H., & Coffman, T. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113640 · Cited by 278
Yang, X. D., Ai, W., Asfaha, S., Bhagat, G., Friedman, R. A., Jin, G., Park, H., Shykind, B., Diacovo, T. G., Falus, A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2278 · Cited by 233
Lu-Emerson, C., Snuderl, M., Kirkpatrick, N. D., Goveia, J., Davidson, C., Huang, Y., Riedemann, L., Taylor, J., Ivy, P., Duda, D. G., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not082 · Cited by 226 · cited 1×
“TAMs accumulation is associated with poor prognosis and is a potential diagnostic biomarker for treatment stratification (Steidl et al, 2010; Lu-Emerson et al, 2013).”
BackgroundSvoronos, N., Perales-Puchalt, A., Allegrezza, M. J., Rutkowski, M. R., Payne, K. K., Tesone, A. J., Nguyen, J. M., Curiel, T. J., Cadungog, M. G., Singhal, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0502 · Cited by 217 · cited 2×
“Thereafter, we assessed the effect of TP16 on MDSC differentiation and expansion using a GM-CSF/IL-6/ PGE2-derived MDSC differentiation model (Svoronos et al, 2017).”
MethodNSAIDs Inhibit Tumorigenesis, but How?
Gurpinar, E., Grizzle, W. E., & Piazza, G. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1573 · Cited by 216 · cited 1×
“Several studies have shown that COX inhibitors, which include nonsteroidal anti-inflammatory drugs (NSAIDs), reduce the risk of cancer incidence and death due to advanced malignant diseases such as colorectal cancer (Thun et al, 2002; Gurpinar et al, 2014).”
BackgroundWu, V., Yeerna, H., Nohata, N., Chiou, J., Harismendy, O., Raimondi, F., Inoue, A., Russell, R. B., Tamayo, P., & Gutkind, J. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.005601 · Cited by 179 · cited 5×
“EP4 is the master regulator of IMCs EP1-4 constitutes a subfamily of cell surface receptors of the immunosuppressive molecule, PGE2.”
BackgroundInfluentialProstaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?
O'Callaghan, G., & Houston, A. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13331 · Cited by 176
Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization
Tan, B., Shi, X., Zhang, J., Qin, J., Zhang, N., Ren, H., Qian, M., Siwko, S., Carmon, K., Liu, Q., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0152 · Cited by 165 · cited 3×
“For macrophages analysis (De Henau et al, 2016; Tan et al, 2018), mouse BM cells were polarized into M1 macrophages or M2 macrophages using IFN-c or IL-4, respectively.”
MethodSelf-citationStructural features of subtype-selective EP receptor modulators
Markovič, T., Jakopin, Ž., Dolenc, M. S., & Mlinarič-Raščan, I. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.003 · Cited by 159 · cited 2×
“Grapiprant is the most advanced EP4 antagonist (phase II) for the treatment of advanced solid tumors; however, its unsatisfactory pharmacokinetic profiles may hinder its clinical efficacy (Markovic et al, 2017).”
BackgroundAl-Khami, A. A., Hossain, F., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Del Valle, L., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o18 · Cited by 150
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Wang, Z., Till, B. G., & Gao, Q. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331807 · Cited by 148 · cited 1×
“…functions of IMCs include traditional chemotherapeutic agents such as gemcitabine, 5-fluorouracil, doxorubicin, and paclitaxel as well as recently found agents that reduce MDSCs levels at the tumor sites and in peripheral lymphoid organs in certain therapeutic schedules (Wang et al, 2017).”
BackgroundOverman, M. J., Ernstoff, M. S., & Morse, M. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200821 · Cited by 145 · cited 1×
“However, the activity is lost in the microsatellite-stable (MSS) population, representing the majority of colorectal cancer patients (Pitt et al, 2016; Overman et al, 2018).”
BackgroundRodríguez‐Ubreva, J., Català‐Moll, F., Obermajer, N., Álvarez‐Errico, D., Ramírez, R. N., Vento‐Tormo, R., Moreno‐Bueno, G., Edwards, R. P., Mortazavi, A., Kaliński, P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.018 · Cited by 134 · cited 1×
“…to reduce the differentiation of monocytic MDSC (mMDSCs, Ly6C+Ly6G CD11b+) but not polymorphonuclear MDSC (PMNMDSCs, Ly6CmidLy6G+CD11b+), which is consistent with 4 of 20 EMBO Molecular Medicine 13: e12798 | 2021 ª 2020 The Authors previous studies (Shi et al, 2014; Rodriguez-Ubreva et al, 2017).”
ResultLigand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface
Toyoda, Y., Morimoto, K., Suno, R., Horita, S., Yamashita, K., Hirata, K., Sekiguchi, Y., Yasuda, S., Shiroishi, M., Shimizu, T., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0131-3 · Cited by 125 · cited 2×
“The crystal structure of human EP4 bound to ONOAE3-208 was retrieved from the Protein Data Bank (PDB ID: 5YWY) (Toyoda et al, 2019).”
BackgroundMethodGeneration of myeloid-derived suppressor cells using prostaglandin E2
Obermajer, N., & Kaliński, P. (2012) · Transplantation Research · doi:10.1186/2047-1440-1-15 · Cited by 123 · cited 1×
“Prostaglandin E2 (PGE2), a bioactive lipid with pro-tumor activity, acts through several mechanisms in colorectal cancer (Obermajer & Kalinski, 2012; Luan et al, 2015; Martinez-Colon & Moore, 2018).”
BackgroundProstaglandin E 2 as a Regulator of Immunity to Pathogens
Martínez-Colón, G. J., & Moore, B. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.008 · Cited by 109
Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs)
Sica, A., Porta, C., Morlacchi, S., Banfi, S., Strauss, L., Rimoldi, M., Totaro, M. G., & Riboldi, E. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0091-6 · Cited by 101
Albu, D. I., Wang, Z., Huang, K.-C., Wu, J., Twine, N., Leacu, S., Ingersoll, C., Parent, L., Lee, W., Liu, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338239 · Cited by 92 · cited 2×
“Notably, TP-16 showed greater efficacy than E7046, a selective EP4 antagonist in phase I trials (Albu et al, 2017), at the same dosage (150 mg/kg, Fig 3B).”
BackgroundPTGES/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model
Wang, T., Jing, B., Xu, D., Liao, Y., Song, H., Sun, B., Guo, W., Xu, J., Li, K., Hu, M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1207-6 · Cited by 86 · cited 1×
“Recently, Deng et al reported that a prostaglandin E Synthase inhibitor (Cay10526) suppressed tumor malignant progression in a spontaneous lung adenocarcinoma model (Wang et al, 2020); however, its clinical benefits require further investigation.”
BackgroundA Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H., Brodsky, A. N., Chan, E., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 69 · cited 2×
“Colorectal cancer, especially the MMS genotype, is largely resistant to immunotherapy (Le et al, 2017).”
BackgroundShi, M., Shi, G., Tang, J., Kong, D., Bao, Y., Xiao, B., Zuo, C., Wang, T., Wang, Q., Shen, Y., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.04.035 · Cited by 47 · cited 1×
“…to reduce the differentiation of monocytic MDSC (mMDSCs, Ly6C+Ly6G CD11b+) but not polymorphonuclear MDSC (PMNMDSCs, Ly6CmidLy6G+CD11b+), which is consistent with 4 of 20 EMBO Molecular Medicine 13: e12798 | 2021 ª 2020 The Authors previous studies (Shi et al, 2014; Rodriguez-Ubreva et al, 2017).”
ResultProstaglandin E receptor 4 (EP4) promotes colonic tumorigenesis
Chang, J. H., Vacher, J., Yao, B., Fan, X., Zhang, B., Harris, R. C., & Zhang, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5589 · Cited by 45 · cited 1×
“Furthermore, a specific role of EP4, but not of other EP subtypes, has been reported in human and mousederived myeloid cell differentiation and function (Chang et al, 2015; Albu et al, 2017).”
BackgroundHite, N., Klinger, A. L., Hellmers, L., Maresh, G. A., Miller, P. E., Zhang, X., Li, L., & Margolin, D. A. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001096 · Cited by 44 · cited 1×
“An orthotopic colon cancer model was established as described previously (Hite et al, 2018; Song et al, 2018).”
MethodChiappa, A., Makuuchi, M., Lygidakis, N. J., Zbar, A. P., Chong, G., Bertani, E., Sitzler, P. J., Biffi, R., Pace, U., Bianchi, P. P., et al. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.11.003 · Cited by 35 · cited 1×
“Approximately 20% of patients have distant metastatic disease at initial diagnosis, and half of the patients develop metastases during disease progression (Chiappa et al, 2009).”
BackgroundWu, Z., Lü, W., Yu, W., Wang, T., Li, W., Liu, G., Zhang, H., Pang, X., Huang, J. Y., Liu, M., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.005 · Cited by 31 · cited 2×
“The CHO-Ga16 cell line was established in our previous study and maintained in DMEM/F12 medium containing puromycin (4 lg/ml) (Wu et al, 2018).”
BackgroundMethodSelf-citation
Cited by
The cancer metabolic reprogramming and immune response
Xia, L., Oyang, L., Lin, J., Tan, S., Han, Y., Wu, N., Yi, P., Tang, L., Pan, Q., Rao, S., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01316-8 · Cited by 1,312
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Gong, Z., Li, Q., Shi, J., Wei, J., Li, P., Chang, C.-H., Shultz, L. D., & Ren, G. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.001 · Cited by 239
Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells
Jin, K., Qian, C., Lin, J., & Liu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1099811 · Cited by 182
“Emerging data from multiple solid tumor mouse models indicates that EP4 antagonists and PD1/PD-L1 blockade are effective in inhibiting primary tumor growth (49, 95, 96).”
BackgroundRegulatory cells and the effect of cancer immunotherapy
Iglesias-Escudero, M., Arias-González, N., & Martínez-Cáceres, E. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01714-0 · Cited by 191
Metadata
- Authors
- Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., Zhang, Q., Yang, H., Peng, S., Yi, Z., Ren, S., Chen, J., Siwko, S., Nussinov, R., Cheng, F., Zhang, H., & Liu, M.
- Affiliations
- East China Normal University (CN)
- Second Military Medical University (CN)
- Ningxia Medical University (CN)
- Texas A&M University (US)
- Tel Aviv University (IL)
- Cleveland Clinic (US)
- Corresponding author
- Zhang, Hankun
- Liu, Mingyao
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-12-07
- Volume
- 13
- Issue
- 1
- Pages
- e12798-e12798
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7799360
- OpenAlex
- W3112267375
- Cited by
- 112
- References
- 66
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 27 · 2023: 25 · 2022: 21 · 2021: 14 · 2020: 1
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81972828, 81830083, 21977032, 2020ZX09201‐003)
- Shanghai Municipal Education Commission (2017‐01‐07‐00‐05‐E00011)
- Shenzhen (KQTD2017081060226082)
- Shanghai Committee of Science and Technology (18431900500, 19ZR1473500, 18431900100)
- National Key R&D Program of China (2018YFA0507000)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- colorectal cancer, EP4 receptor, prostaglandin E2, immunosuppressive myeloid cells, M2 macrophages, myeloid-derived suppressor cells, EP4 antagonist, immune checkpoint inhibitor resistance, anti-PD-1 combination therapy, T cell proliferation, tumor immunosuppression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Immunotherapy, Colorectal Neoplasms, Myeloid Cells, Mice, Receptors, Prostaglandin E, EP4 Subtype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.